Targeting slow-proliferating ovarian cancer cells

International Journal of Cancer

Volumn 126, Issue 10, 2010, Pages 2448-2456

  Kondoh, Eiji ^a,b   Mori, Seiichi ^c   Yamaguchi, Ken ^a,b   Baba, Tsukasa ^b   Matsumura, Noriomi ^b   Barnett, J Cory ^a   Whitaker, Regina S ^a   Konishi, Ikuo ^b   Fujii, Shingo ^d   Berchuck, Andrew ^a,c   Murphy, Susan K ^a,c  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b KYOTO UNIVERSITY   (Japan)

^c DUKE UNIVERSITY   (United States)

^d NATIONAL HOSPITAL ORGANIZATION KYOTO MEDICAL CENTER   (Japan)

Author keywords

Drug resistance; Ki 67; Ovarian cancer; Proliferation; Quiescence

Indexed keywords

7 HYDROXYSTAUROSPORINE; CASPASE 3; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; IRINOTECAN; KI 67 ANTIGEN; OLTIPRAZ; PACLITAXEL; SIMVASTATIN; STAUROSPORINE; TOPOTECAN; 7-HYDROXYSTAUROSPORINE; ANTINEOPLASTIC AGENT; CYTOSTATIC AGENT; DRUG DERIVATIVE; PROTEIN KINASE C; PROTEIN KINASE INHIBITOR;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER REGRESSION; CELL POPULATION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOSTASIS; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG TARGETING; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVARY CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; SECOND LOOK SURGERY; CARCINOMA; CHEMISTRY; DRUG ANTAGONISM; DRUG EFFECT; KAPLAN MEIER METHOD; OVARY TUMOR; PATHOLOGY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CARCINOMA; CASPASE 3; CELL LINE, TUMOR; CELL PROLIFERATION; CYTOSTATIC AGENTS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIERS ESTIMATE; KI-67 ANTIGEN; OVARIAN NEOPLASMS; PROTEIN KINASE C; PROTEIN KINASE INHIBITORS; STAUROSPORINE;

EID: 77951221534     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.24919     Document Type: Article

References (39)

1. Dressman HK, Berchuck A, Chan G, Zhai J, Bild A, Sayer R, Cragun J, Clarke J, Whitaker RS, Li L, Gray J, Marks J, et al. An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer. J Clin Oncol 2007;25:517-525
2. Cannistra SA. Cancer of the ovary. N Engl J Med 2004;351:2519-2529
3. Agarwal R, Kaye SB. Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer 2003;3: 502-516 (Pubitemid 37328838)
4. Jazaeri AA, Awtrey CS, Chandramouli GV, Chuang YE, Khan J, Sotiriou C, Aprelikova O, Yee CJ, Zorn KK, Birrer MJ, Barrett JC, Boyd J. Gene expression profiles associated with response to chemotherapy in epithelial ovarian cancers. Clin Cancer Res 2005;11:6300-6310 (Pubitemid 41262961)
5. Tredan O, Galmarini CM, Patel K, Tannock IF. Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst 2007;99:1441-1454
6. Weinstein JN, Myers TG, O'Connor PM, Friend SH, Fornace AJ, Jr, Kohn KW, Fojo T, Bates SE, Rubinstein LV, Anderson NL, Buolamwini JK, van Osdol WW, et al. An information-intensive approach to the molecular pharmacology of cancer. Science 1997;275:343-349 (Pubitemid 27051604)
7. Whitfield ML, George LK, Grant GD, Perou CM. Common markers of proliferation. Nat Rev Cancer 2006;6: 99-106.
8. de Hoon MJ, Imoto S, Nolan J, Miyano S. Open source clustering software. Bioinformatics 2004;20:1453-1454
9. Bild AH, Yao G, Chang JT, Wang Q, Potti A, Chasse D, Joshi MB, Harpole D, Lancaster JM, Berchuck A, Olson JA, Jr, Marks JR, et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 2006;439:353-357 (Pubitemid 43128862)
10. Jasny BR, Pfeffer LM, Tamm I. Effects of beta interferon on human fibroblasts at different population doubling levels. Proliferation, cell volume, thymidine uptake, and DNA synthesis. J Exp Med 1984;159:1741-1749 (Pubitemid 14117080)
11. Marchesini N, Osta W, Bielawski J, Luberto C, Obeid LM, Hannun YA. Role for mammalian neutral sphingomyelinase 2 in confluence-induced growth arrest of MCF7 cells. J Biol Chem 2004;279: 25101-25111 (Pubitemid 38756759)
12. Litovchick L, Sadasivam S, Florens L, Zhu X, Swanson SK, Velmurugan S, Chen R, Washburn MP, Liu XS, DeCaprio JA. Evolutionarily conserved multisubunit RBL2/p130 and E2F4 protein complex represses human cell cycle-dependent genes in quiescence. Mol Cell 2007;26:539-551 (Pubitemid 46779093)
13. Dupont J, Aghajanian C, Sabbatini P, Spriggs DR. New agents for the treatment of ovarian cancer: the next generation. Int J Gynecol Cancer 2005;15(Suppl 3):252-257 (Pubitemid 43096591)
14. Goldie JH, Coldman AJ. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer. Treat Rep 1979;63:1727-1733
15. Graves PR, Yu L, Schwarz JK, Gales J, Sausville EA, O'Connor PM, Piwnica-Worms H. The Chk1 protein kinase and the Cdc25C regulatory pathways are targets of the anticancer agent UCN-01. J Biol Chem 2000;275:5600-5605 (Pubitemid 30115197)
16. Sugiyama K, Akiyama T, Shimizu M, Tamaoki T, Courage C, Gescher A, Akinaga S. Decrease in susceptibility toward induction of apoptosis and alteration in G1 checkpoint function as determinants of resistance of human lung cancer cells against the antisignaling drug UCN-01 (7-hydroxystaurosporine). Cancer Res 1999;59:4406-4412 (Pubitemid 29418761)
17. Wang Q, Worland PJ, Clark JL, Carlson BA, Sausville EA. Apoptosis in 7-hydroxystaurosporine-treated T lymphoblasts correlates with activation of cyclin-dependent kinases 1 and 2. Cell Growth Differ 1995;6:927-936
18. Akiyama T, Yoshida T, Tsujita T, Shimizu M, Mizukami T, Okabe M, Akinaga S. G1 phase accumulation induced by UCN-01 is associated with dephosphorylation of Rb and CDK2 proteins as well as induction of CDK inhibitor p21/Cip1/WAF1/Sdi1 in p53-mutated human epidermoid carcinoma A431 cells. Cancer Res 1997;57:1495-1501 (Pubitemid 27175566)
19. Welch S, Hirte HW, Carey MS, Hotte SJ, Tsao MS, Brown S, Pond GR, Dancey JE, Oza AM. UCN-01 in combination with topotecan in patients with advanced recurrent ovarian cancer: a study of the Princess Margaret Hospital Phase II consortium. Gynecol Oncol 2007;106: 305-310 (Pubitemid 47096653)
20. Shah MA, Schwartz GK. Cell cycle-mediated drug resistance: an emerging concept in cancer therapy. Clin Cancer Res 2001;7:2168-2181
21. Fuse E, Tanii H, Kurata N, Kobayashi H, Shimada Y, Tamura T, Sasaki Y, Tanigawara Y, Lush RD, Headlee D, Figg WD, Arbuck SG, et al. Unpredicted clinical pharmacology of UCN-01 caused by specific binding to human alpha1-acid glycoprotein. Cancer Res 1998;58:3248-3253 (Pubitemid 28371060)
22. Wong WW, Dimitroulakos J, Minden MD, Penn LZ. HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis. Leukemia 2002;16:508-519 (Pubitemid 34460459)
23. Kawamata S, Sakaida H, Hori T, Maeda M, Uchiyama T. The upregulation of p27Kip1 by rapamycin results in G1 arrest in exponentially growing T-cell lines. Blood 1998;91:561-569 (Pubitemid 28053379)
24. Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 1999;13: 1501-1512
25. Lin YC, Lin JH, Chou CW, Chang YF, Yeh SH, Chen CC. Statins increase p21 through inhibition of histone deacetylase activity and release of promoter-associated HDAC1/2. Cancer Res 2008;68:2375-2383
26. Piton A, Le Ferrec E, Langouet S, Rauch C, Petit E, Le Goff F, Guillouzo A, Morel F. Oltipraz regulates different categories of genes relevant to chemoprevention in human hepatocytes. Carcinogenesis 2005; 26:343-351 (Pubitemid 40246555)
27. Cheng T, Rodrigues N, Shen H, Yang Y, Dombkowski D, Sykes M, Scadden DT. Hematopoietic stem cell quiescence maintained by p21cip1/waf1. Science 2000; 287:1804-1808
28. Iida K, Itoh K, Kumagai Y, Oyasu R, Hattori K, Kawai K, Shimazui T, Akaza H, Yamamoto M. Nrf2 is essential for the chemopreventive efficacy of oltipraz against urinary bladder carcinogenesis. Cancer Res 2004;64:6424-6431 (Pubitemid 39297896)
29. Hartmann LC, Sebo TJ, Kamel NA, Podratz KC, Cha SS, Wieand HS, Keeney GL, Roche PC. Proliferating cell nuclear antigen in epithelial ovarian cancer: relation to results at second-look laparotomy and survival. Gynecol Oncol 1992;47:191-195
30. Itamochi H, Kigawa J, Sugiyama T, Kikuchi Y, Suzuki M, Terakawa N. Low proliferation activity may be associated with chemoresistance in clear cell carcinoma of the ovary. Obstet Gynecol 2002;100:281-287 (Pubitemid 34874791)
31. Moreno CS, Matyunina L, Dickerson EB, Schubert N, Bowen NJ, Logani S, Benigno BB, McDonald JF. Evidence that p53-mediated cell-cycle-arrest inhibits chemotherapeutic treatment of ovarian carcinomas. PLoS ONE 2007;2: e441.
32. Anttila M, Kosma VM, Ji H, Wei-Ling X, Puolakka J, Juhola M, Saarikoski S, Syrjanen K. Clinical significance of alpha-catenin, collagen IV, and Ki-67 expression in epithelial ovarian cancer. J Clin Oncol 1998;16:2591-2600 (Pubitemid 28363021)
33. Goff BA, Muntz HG, Greer BE, Tamimi HK, Gown AM. Oncogene expression: long-term compared with short-term survival in patients with advanced epithelial ovarian cancer. Obstet Gynecol 1998;92:88-93. (Pubitemid 28285327)
34. Kaern J, Aghmesheh M, Nesland JM, Danielsen HE, Sandstad B, Friedlander M, Trope C. Prognostic factors in ovarian carcinoma stage III patients. Can biomarkers improve the prediction of short- and long-term survivors? Int J Gynecol Cancer 2005;15:1014-1022
35. Khouja MH, Baekelandt M, Nesland JM, Holm R. The clinical importance of Ki-67, p16, p14, and p57 expression in patients with advanced ovarian carcinoma. Int J Gynecol Pathol 2007;26:418-425
36. Kritpracha K, Hanprasertpong J, Chandeying V, Dechsukhum C, Geater A. Survival analysis in advanced epithelial ovarian carcinoma in relation to proliferative index of MIB-1 immunostaining. J Obstet Gynaecol Res 2005;31:268-276 (Pubitemid 40943740)
37. Urruticoechea A, Smith IE, Dowsett M. Proliferation marker Ki-67 in early breast cancer. J Clin Oncol 2005;23:7212-7220 (Pubitemid 46260309)
38. Halvorsen OJ, Haukaas SA, Akslen LA. Combined loss of PTEN and p27 expression is associated with tumor cell proliferation by Ki-67 and increased risk of recurrent disease in localized prostate cancer. Clin Cancer Res 2003;9:1474-1479
39. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T, Hiller W, Fisher ER, et al. A multigene assay to predict recurrence of tamoxifen-treated, nodenegative breast cancer. N Engl J Med 2004; 351:2817-2826